Chris Howerton
Stock Analyst at Jefferies
(2.64)
# 2,215
Out of 5,058 analysts
70
Total ratings
45.45%
Success rate
17.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.57 | +43.63% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $36.51 | +116.38% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.33 | +71.67% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.39 | +318.41% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.74 | +20,129.89% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $17.59 | +3,993.23% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.63 | -69.23% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $25.27 | -60.43% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $23.10 | -52.38% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $19.45 | +105.66% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $33.31 | +83.13% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $146.77 | -38.68% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $5.14 | +133.46% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.75 | +2,560.99% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $24.92 | +164.85% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.42 | +397.74% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.03 | +1,938.83% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.92 | +2,279.15% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.81 | +1,170.72% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $23.10 | -9.09% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $28.63 | +1,925.85% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.65 | +3,536.36% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $76.10 | -78.98% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $85.13 | -68.28% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $3.47 | +34,482.13% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.57
Upside: +43.63%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $36.51
Upside: +116.38%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.33
Upside: +71.67%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.39
Upside: +318.41%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.74
Upside: +20,129.89%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $17.59
Upside: +3,993.23%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.63
Upside: -69.23%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $25.27
Upside: -60.43%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $23.10
Upside: -52.38%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $19.45
Upside: +105.66%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $33.31
Upside: +83.13%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $146.77
Upside: -38.68%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $5.14
Upside: +133.46%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.75
Upside: +2,560.99%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $24.92
Upside: +164.85%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $4.42
Upside: +397.74%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.03
Upside: +1,938.83%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.92
Upside: +2,279.15%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.81
Upside: +1,170.72%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $23.10
Upside: -9.09%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $28.63
Upside: +1,925.85%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.65
Upside: +3,536.36%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $76.10
Upside: -78.98%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $85.13
Upside: -68.28%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $3.47
Upside: +34,482.13%